U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C8H11N5O3
Molecular Weight 225.2046
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ACYCLOVIR

SMILES

NC1=NC2=C(N=CN2COCCO)C(=O)N1

InChI

InChIKey=MKUXAQIIEYXACX-UHFFFAOYSA-N
InChI=1S/C8H11N5O3/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14/h3,14H,1-2,4H2,(H3,9,11,12,15)

HIDE SMILES / InChI
Molecular Formula C8H11N5O3
Molecular Weight 225.2046
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/6313598 | https://www.ncbi.nlm.nih.gov/pubmed/2828440 | https://www.ncbi.nlm.nih.gov/pubmed/202961

Acyclovir is a synthetic antiviral nucleoside analogue. A screening program for antiviral drugs begun at Burroughs Wellcome in the 1960s resulted in the discovery of acyclovir in 1974. Preclinical investigation brought the drug to clinical trials in 1977 and the first form of the drug (topical) was available to physicians in 1982. Activity of acyclovir is greatest against herpes 1 and herpes 2, less against varicella zoster, still less against Epstein-Barr, and very little against cytomegalovirus. Acyclovir is an antiviral agent only after it is phosphorylated in infected cells by a viral-induced thymidine kinase. Acyclovir monophosphate is phosphorylated to diphosphate and triphosphate forms by cellular enzymes in the infected host cell where the drug is concentrated. Acyclovir triphosphate inactivates viral deoxyribonucleic acid polymerase.

CNS Activity

CNS Penetrant
2588
Curator's Comment: Valacyclovir hydrochloride is rapidly converted to acyclovir which was detected in CSF after oral administration of valacyclovir.

Originator

Approval Year

1982
105
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
Inhibitor
8504
 0.08 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
ZOVIRAX

Approved Use

Oral ZOVIRAX® (acyclovir) is indicated for the treatment: Herpes Zoster Infections: ZOVIRAX is indicated for the acute treatment of herpes zoster (shingles). Genital Herpes: ZOVIRAX is indicated for the treatment of initial episodes and the management of recurrent episodes of genital herpes. Chickenpox: ZOVIRAX is indicated for the treatment of chickenpox (varicella). Injectable ZOVIRAX® (acyclovir) is indicated for the treatment: Herpes Simplex Infections in Immunocompromised Patients: ZOVIRAX for Injection is indicated for the treatment of initial and recurrent mucosal and cutaneous herpes simplex (HSV-1 and HSV-2) in immunocompromised patients. Initial Episodes of Herpes Genitalis: ZOVIRAX for Injection is indicated for the treatment of severe initial clinical episodes of herpes genitalis in immunocompetent patients. Herpes Simplex Encephalitis: ZOVIRAX for Injection is indicated for the treatment of herpessimplex encephalitis. Neonatal Herpes Simplex Virus Infection: ZOVIRAX for Injection is indicated for the treatmentof neonatal herpes infections. Varicella-Zoster Infections in Immunocompromised Patients: ZOVIRAX for Injection is indicated for the treatment of varicella-zoster (shingles) infections in immunocompromised patients.

Launch Date

1982
Primary
Approved
8583
ZOVIRAX

Approved Use

Oral ZOVIRAX® (acyclovir) is indicated for the treatment: Herpes Zoster Infections: ZOVIRAX is indicated for the acute treatment of herpes zoster (shingles). Genital Herpes: ZOVIRAX is indicated for the treatment of initial episodes and the management of recurrent episodes of genital herpes. Chickenpox: ZOVIRAX is indicated for the treatment of chickenpox (varicella). Injectable ZOVIRAX® (acyclovir) is indicated for the treatment: Herpes Simplex Infections in Immunocompromised Patients: ZOVIRAX for Injection is indicated for the treatment of initial and recurrent mucosal and cutaneous herpes simplex (HSV-1 and HSV-2) in immunocompromised patients. Initial Episodes of Herpes Genitalis: ZOVIRAX for Injection is indicated for the treatment of severe initial clinical episodes of herpes genitalis in immunocompetent patients. Herpes Simplex Encephalitis: ZOVIRAX for Injection is indicated for the treatment of herpessimplex encephalitis. Neonatal Herpes Simplex Virus Infection: ZOVIRAX for Injection is indicated for the treatmentof neonatal herpes infections. Varicella-Zoster Infections in Immunocompromised Patients: ZOVIRAX for Injection is indicated for the treatment of varicella-zoster (shingles) infections in immunocompromised patients.

Launch Date

1982
Primary
Approved
8583
VALTREX

Approved Use

INDICATIONS AND USAGE. VALTREX is a nucleoside analogue DNA polymerase inhibitor indicated for: Adult Patients Cold Sores (Herpes Labialis), Genital Herpes, Treatment in immunocompetent patients (initial or recurrent episode), Suppression in immunocompetent or HIV-infected patients, Reduction of transmission, Herpes Zoster. Pediatric Patients Cold Sores (Herpes Labialis), Chickenpox Limitations of Use. The efficacy and safety of VALTREX have not been established in immunocompromised patients other than for the suppression of genital herpes in HIV-infected patients.

Launch Date

2004
Primary
Approved
8583
VALTREX

Approved Use

INDICATIONS AND USAGE. VALTREX is a nucleoside analogue DNA polymerase inhibitor indicated for: Adult Patients Cold Sores (Herpes Labialis), Genital Herpes, Treatment in immunocompetent patients (initial or recurrent episode), Suppression in immunocompetent or HIV-infected patients, Reduction of transmission, Herpes Zoster. Pediatric Patients Cold Sores (Herpes Labialis), Chickenpox Limitations of Use. The efficacy and safety of VALTREX have not been established in immunocompromised patients other than for the suppression of genital herpes in HIV-infected patients.

Launch Date

2004
Primary
Approved
8583
VALTRE

Approved Use

INDICATIONS AND USAGE. VALTREX is a nucleoside analogue DNA polymerase inhibitor indicated for: Adult Patients Cold Sores (Herpes Labialis), Genital Herpes, Treatment in immunocompetent patients (initial or recurrent episode), Suppression in immunocompetent or HIV-infected patients, Reduction of transmission, Herpes Zoster. Pediatric Patients Cold Sores (Herpes Labialis), Chickenpox Limitations of Use. The efficacy and safety of VALTREX have not been established in immunocompromised patients other than for the suppression of genital herpes in HIV-infected patients.

Launch Date

2004
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
599.2 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/17692728
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ACYCLOVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3015.7 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/17692728
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ACYCLOVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.9 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/17692728
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ACYCLOVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
79%
EXPERIMENT
https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/018828s030,020089s019,019909s020lbl.pdf
ACYCLOVIR plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
OAT1
725

OAT2
153

OAT3
747

OAT4
150

OCT1
620

OCT2
779

OATP1B1
1079

OATP1B3
961

OATP2B1
157

CYP1A2
2153
OAT1
395

OAT2
125

OAT3
391

OAT4
93

OCT1
393

OCT2
434

MRP2
252

MATE1
182

MATE2
98

BCRP
697
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
OAT2
155
 no
OAT4
150
 no
OATP1B1
1095
 no
OATP1B3
970
 no
OATP2B1
162
 no
OCT2
782
 no
CYP1A2
2333
 weak
OAT1
730
 yes
OAT3
749
 yes
OCT1
656
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
OAT2
125
 no
OAT3
391
 no
OAT4
93
 no
OCT2
434
 no
BCRP
697
 yes
MATE1
182
 yes
MATE2
98
 yes
MRP2
252
 yes
OAT1
395
 yes
OCT1
393
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:2453
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:2453
ChemicalBook
CB7126677
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7126677
eMolecules
29702921
https://www.emolecules.com/cgi-bin/more?vid=29702921
eMolecules
768732
https://www.emolecules.com/cgi-bin/more?vid=768732
eMolecules
901331
https://www.emolecules.com/cgi-bin/more?vid=901331
MolPort
MolPort-000-768-994
https://www.molport.com/shop/molecule-link/MolPort-000-768-994
MolPort
MolPort-001-889-834
https://www.molport.com/shop/molecule-link/MolPort-001-889-834
MolPort
MolPort-003-940-063
https://www.molport.com/shop/molecule-link/MolPort-003-940-063
Selleck Chemicals
Acyclovir(Aciclovir)
http://www.selleckchem.com/products/Acyclovir(Aciclovir).html
ZINC
ZINC000001530555
http://zinc15.docking.org/substances/ZINC000001530555
PubMed

PubMed

TitleDatePubMed
Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir].
1989 Oct
Hepatic and renal effects of azidothymidine and acyclovir on pregnant rats.
2000
Guanosine analogues as anti-herpesvirus agents.
2000 Oct-Dec
A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients.
2001
Interventions for herpes simplex virus epithelial keratitis.
2001
Prophylaxis against herpesvirus infections in transplant recipients.
2001
Management of neonatal herpes simplex virus infection.
2001
Recent advances in imaging endogenous or transferred gene expression utilizing radionuclide technologies in living subjects: applications to breast cancer.
2001
Heart transplantation and the Batista operation for children with refractory heart failure.
2001 Apr
Treatment of EBV driven lymphoproliferation with erythrophagocytosis: 12 year follow up.
2001 Apr
Famciclovir vs. aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-groups, randomized, double-blind clinical trial.
2001 Apr
[Peptide transporter family].
2001 Apr
Acyclovir treatment in 2 patients with benign trigeminal sensory neuropathy.
2001 Apr
Biological characterization of eugeniin as an anti-herpes simplex virus type 1 compound in vitro and in vivo.
2001 Apr
Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing.
2001 Apr 1
Practice parameter: Steroids, acyclovir, and surgery for Bell's palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
2001 Apr 10
Hydrophilic interaction chromatography using amino and silica columns for the determination of polar pharmaceuticals and impurities.
2001 Apr 13
Postherpetic neuralgia. Treatment with amitriptyline is cheaper than with aciclovir.
2001 Apr 7
Postherpetic neuralgia. Pathogenesis of postherpetic neuralgia should be determined.
2001 Apr 7
[Photoallergy to Zovirax cream].
2001 Feb
Painful skin erosions and fever in an infant. Eczema herpeticum.
2001 Feb
Prophylaxis of intravenous immunoglobulin and acyclovir in perinatal varicella.
2001 Feb
Pretransplant varicella vaccination is cost-effective in pediatric renal transplantation.
2001 Feb
Genetic risks of antiviral nucleoside analogues--a survey.
2001 Feb
Persistent verrucous varicella as the initial manifestation of HIV infection.
2001 Feb
Meta-analysis of prophylaxis of CMV disease in solid organ transplantation: is Ganciclovir a superior agent to Acyclovir?
2001 Feb-Mar
Prophylactic antiviral therapy in CMV high-risk liver transplant recipients.
2001 Feb-Mar
Antiviral drugs can inhibit lymphocyte apoptosis induced by cytomegalovirus antigens.
2001 Feb-Mar
Aerobic bacterial and fungal infections in peripheral blood stem cell transplants.
2001 Jan
[Valaciclovir in the treatment of initial infection by genital herpes virus: comparative study].
2001 Jan
Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation.
2001 Jan 15
Novel synthesis of seco type of acyclo C-nucleosides of 1,2,4-triazole and 1,2,4-triazol.
2001 Jan-Feb
[Highly active antiviral and immunosuppressive combination therapy with acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease].
2001 Mar
[Benign acute ataxia in an adult with VZV infection].
2001 Mar
A pilot study of treatment of herpes labialis with 1072 nm narrow waveband light.
2001 Mar
[Neurologic toxicity caused by zelitrex (valaciclovir) in 3 patients with renal failure. Is overdose associated with improvement of product bioavailability improvement?].
2001 Mar
A 35-year-old man with recurrent aseptic meningitis.
2001 Mar
Ocular tolerability and in vivo bioavailability of poly(ethylene glycol) (PEG)-coated polyethyl-2-cyanoacrylate nanosphere-encapsulated acyclovir.
2001 Mar
The management of varicella-zoster virus exposure and infection in pregnancy and the newborn period. Australasian Subgroup in Paediatric Infectious Diseases of the Australasian Society for Infectious Diseases.
2001 Mar 19
Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study.
2001 Mar-Apr
[Intrauterine herpes simplex virus infection].
2001 Mar-Apr
Coexpression of guanylate kinase with thymidine kinase enhances prodrug cell killing in vitro and suppresses vascular smooth muscle cell proliferation in vivo.
2001 May
Famciclovir for ophthalmic zoster: a randomised aciclovir controlled study.
2001 May
Acyclovir prophylaxis in late pregnancy prevents recurrent genital herpes and viral shedding.
2001 May
Contact dermatitis from topical antiviral drugs.
2001 May
Chemical stability, enzymatic hydrolysis, and nasal uptake of amino acid ester prodrugs of acyclovir.
2001 May
Enhancement of the anti-herpetic effect of trichosanthin by acyclovir and interferon.
2001 May 11
Synthesis and biological evaluation of purine-containing butenolides.
2001 May 24
FV-100 versus valacyclovir for the prevention of post-herpetic neuralgia and the treatment of acute herpes zoster-associated pain: A randomized-controlled trial.
2017 Jul
Diagnosis and Treatment of Acute Retinal Necrosis: A Report by the American Academy of Ophthalmology.
2017 Mar
Patents

Patents

04146715
11
04199574
9
05565565
9
05567816
8
05583225
8
05688948
8
06107302
8
06262254
8
06887997
8
JP2008510795A
76
JP2009501065A
33
JP2010530906A
11
JP2011528275A
456
JP2012500104A
108
JP2873313B2
8
JP4503896B2
20
JPH04139130A
8
JPH05255329A
8
JPH07258256A
8
JPH09136842A
8
US20070021444
8
WO2016201306
8

Sample Use Guides

In Vivo Use Guide
Valacyclovir may be given without regard to meals. Cold Sores (Herpes Labialis): The recommended dosage of Valacyclovir for treatment of cold sores is 2 grams twice daily for 1 day taken 12 hours apart. Therapy should be initiated at the earliest symptom of a cold sore. Genital Herpes: Initial Episode: The recommended dosage of Valacyclovir for treatment of initial genital herpes is 1 gram twice daily for 10 days. Therapy was most effective when administered within 48 hours of the onset of signs and symptoms. Recurrent Episodes: The recommended dosage of Valacyclovir for treatment of recurrent genital herpes is 500 mg twice daily for 3 days. Initiate treatment at the first sign or symptom of an episode.
Route of Administration: Oral
In Vitro Use Guide
In uptake studies using valacyclovir, the extraction solution (water/methanol, 50:50) was added to the Caco-2 cells after the uptake period. After standing for 1 h at room temperature, the solutions were centrifuged and the supernatants were filtered. The filtrate was analyzed by highperformance liquid chromatography (HPLC). Valacyclovir showed a marked inhibitory effect (K=440 +/- 29mkM) on [14C]glycylsarcosine uptake via the apical PEPT1.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:56:13 GMT 2025
Edited
by admin
on Mon Mar 31 17:56:13 GMT 2025
Record UNII
X4HES1O11F
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ACICLOVIR
EP   INN   JAN   MART.   WHO-DD   WHO-IP  
INN  
Preferred Name English
ACYCLOVIR
HSDB   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF  
USAN  
Official Name English
SITAVIG
Brand Name English
ZOVIRAX
Brand Name English
aciclovir [INN]
Common Name English
ACYCLOVIR [VANDF]
Common Name English
NSC-758477
Code English
Aciclovir [WHO-DD]
Common Name English
ACICLOVIR [JAN]
Common Name English
ACYCLOVIR [USP-RS]
Common Name English
ACICLOVIR [WHO-IP]
Common Name English
ACICLOVIR [MART.]
Common Name English
VALACICLOVIR HYDROCHLORIDE HYDRATE IMPURITY B [EP IMPURITY]
Common Name English
ACYCLOVIR [HSDB]
Common Name English
VALACICLOVIR HYDROCHLORIDE IMPURITY B [EP IMPURITY]
Common Name English
GERPEVIR
Common Name English
NOVIRUS
Common Name English
9-[(2-Hydroxyethoxy)methyl]guanine
Systematic Name English
6H-PURIN-6-ONE, 2-AMINO-1,9-DIHYDRO-9-((2-HYDROXYETHOXY)METHYL)-
Systematic Name English
ACYCLOVIR [MI]
Common Name English
ACICLOVIR [IARC]
Common Name English
ACYCLOVIR [ORANGE BOOK]
Common Name English
NSC-645011
Code English
AVACLYR
Brand Name English
ACYCLOVIR [USAN]
Common Name English
ACICLOVIRUM [WHO-IP]
Common Name English
ACICLOVIR [EP MONOGRAPH]
Common Name English
ACYCLOVIR [USP MONOGRAPH]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C281
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
NDF-RT N0000175468
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
NDF-RT N0000175459
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
WHO-VATC QS01AD03
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
FDA ORPHAN DRUG 313210
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
WHO-ESSENTIAL MEDICINES LIST 21.1
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
FDA ORPHAN DRUG 513615
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
WHO-ESSENTIAL MEDICINES LIST 6.4.1
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
WHO-VATC QD06BB53
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
NDF-RT N0000175459
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
NDF-RT N0000180187
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
WHO-ATC D06BB03
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
WHO-ATC D06BB53
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
NCI_THESAURUS C1556
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
WHO-ATC J05AB01
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
FDA ORPHAN DRUG 325010
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
WHO-VATC QD06BB03
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
WHO-VATC QJ05AB01
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
WHO-ATC S01AD03
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
NDF-RT N0000020060
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
LIVERTOX NBK548548
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
NDF-RT N0000180188
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
NCI_THESAURUS C29575
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
FDA ORPHAN DRUG 37589
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
NDF-RT N0000175459
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
Code System Code Type Description
RS_ITEM_NUM
1012065
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
PRIMARY
IUPHAR
4829
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
PRIMARY
EPA CompTox
DTXSID1022556
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
PRIMARY
CAS
59277-89-3
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
PRIMARY
NSC
758477
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
PRIMARY
DRUG CENTRAL
85
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
PRIMARY
DRUG BANK
DB00787
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
PRIMARY
NSC
645011
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
PRIMARY
HSDB
6511
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
PRIMARY
SMS_ID
100000092808
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
PRIMARY
FDA UNII
X4HES1O11F
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
PRIMARY
WIKIPEDIA
ACICLOVIR
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
PRIMARY
CHEBI
2453
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
PRIMARY
ChEMBL
CHEMBL184
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
PRIMARY
LACTMED
Acyclovir
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
PRIMARY
MESH
D000212
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
PRIMARY
NCI_THESAURUS
C205
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
PRIMARY
DAILYMED
X4HES1O11F
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
PRIMARY
INN
4435
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
PRIMARY
ECHA (EC/EINECS)
261-685-1
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
PRIMARY
MERCK INDEX
m1404
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
PRIMARY Merck Index
WHO INTERNATIONAL PHARMACOPEIA
ACYCLOVIR
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
PRIMARY Description: White or almost white, crystalline powder. Solubility: Slightly soluble in water; freely soluble in dimethyl sulfoxide; very slightly soluble in ethanol (96%). It dissolves in dilute solutions of mineral acids and alkali hydroxides. Category: Antiviral (Purine nucleoside analogue). Storage: Preserve in well-closed containers. Protect from light and moisture. Additional information: Aciclovir may exhibit polymorphism. Definition: Aciclovir contains not less than 98.5% and not more than 101.0% of C8H11N5O3, calculated with reference to the dried substance.
RXCUI
281
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
PRIMARY RxNorm
PUBCHEM
135398513
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
PRIMARY
EVMPD
SUB05235MIG
Created by admin on Mon Mar 31 17:56:13 GMT 2025 , Edited by admin on Mon Mar 31 17:56:13 GMT 2025
PRIMARY
Related Record Type Details
MATE-2
TRANSPORTER -> SUBSTRATE
Km
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
acyclovir crosses the placenta
BINDING
MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1
TRANSPORTER -> SUBSTRATE
Km
Structure of ACYCLOVIR
EXCRETED UNCHANGED
URINE
HUMAN HERPESVIRUS 3
TARGET ORGANISM->INHIBITOR
IC50
HUMAN HERPESVIRUS 2
TARGET ORGANISM->INHIBITOR
IC50
ATP-BINDING CASSETTE SUB-FAMILY G MEMBER 2
TRANSPORTER -> SUBSTRATE
HUMAN HERPESVIRUS 1
TARGET ORGANISM->INHIBITOR
IC50
Structure of ACYCLOVIR SODIUM
SALT/SOLVATE -> PARENT
Structure of ACYCLOVIR
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
OCT-1
TRANSPORTER -> SUBSTRATE
MATE-2
TRANSPORTER -> SUBSTRATE
Vmax
MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1
TRANSPORTER -> SUBSTRATE
Vmax
OAT-1
TRANSPORTER -> SUBSTRATE
Structure of 2-((2-ACETAMIDO-6-OXO-1H-PURIN-7(6H)-YL)METHOXY)ETHYL ACETATE
ACTIVE CONSTITUENT ALWAYS PRESENT -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
INTERNATIONAL PHARMACOPEIA
Structure of Acyclovir Sodium Dihydrate
SALT/SOLVATE -> PARENT
OAT-2
TRANSPORTER -> SUBSTRATE
Related Record Type Details
Structure of DESCICLOVIR
PRODRUG -> METABOLITE ACTIVE
Structure of 9-CARBOXYMETHOXYMETHYLGUANINE
METABOLITE -> PARENT
MAJOR
URINE
Structure of Acyclovir triphosphate
METABOLITE ACTIVE -> PARENT
Structure of 8-HYDROXYACYCLOVIR
METABOLITE -> PARENT
MINOR
URINE
Structure of VALACYCLOVIR
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
Structure of Guanine
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of N7-((2-HYDROXYETHOXY)METHYL)GUANINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
INTERNATIONAL PHARMACOPEIA
Structure of 7,9'-(ETHYLENEBIS(OXYMETHYLENE))DIGUANINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
INTERNATIONAL PHARMACOPEIA
Structure of N2,N2'-METHYLENEDIACICLOVIR
IMPURITY -> PARENT
sum of impurities K and R: not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.15 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of VALACYCLOVIR HYDROCHLORIDE MONOHYDRATE
PARENT -> IMPURITY
sum of impurities A and B: maximum 2.0 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of DIACETYLACYCLOVIR
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 2,9-DIACETYLGUANINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 2-((2-ACETAMIDO-6-OXO-1H-PURIN-7(6H)-YL)METHOXY)ETHYL ACETATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
INTERNATIONAL PHARMACOPEIA
Structure of 7,9'-(ETHYLENEBIS(OXYMETHYLENE))DIGUANINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of N2-ACETYLACICLOVIR
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
INTERNATIONAL PHARMACOPEIA
Structure of VALACYCLOVIR HYDROCHLORIDE
PARENT -> IMPURITY
sum of impurities A and B: maximum 2.0 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of O-((GUANIN-9-YL)METHYL) ACYCLOVIR
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
INTERNATIONAL PHARMACOPEIA
Structure of N7-((2-HYDROXYETHOXY)METHYL)GUANINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 9-(2-HYDROXYETHYL)GUANINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 2-amino-9-[[2-(hydroxymethoxy)ethoxy]methyl]-1,9-dihydro-6H-purin-6-one
IMPURITY -> PARENT
sum of impurities O and Q: not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) ( 0.15 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 9-(2-ACETOXYETHOXYMETHYL)GUANINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of Guanine
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
INTERNATIONAL PHARMACOPEIA
Structure of N2,N2'-METHYLENEDIACICLOVIR
IMPURITY -> PARENT
IDENTIFIED AS IMPURITY K The following peaks are eluted at the following relative retention with reference to the peak of aciclovir (retention time about 13 min): impurity K about 2.5.
CHROMATOGRAPHIC PURITY (HPLC/UV)
INTERNATIONAL PHARMACOPEIA
Structure of N2-ACETYLACICLOVIR
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 9-(2-HYDROXYETHYL)GUANINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 2,9-DIACETYLGUANINE
IMPURITY -> PARENT
ACYCLOVIR IMPURITY L AMOUNT NOT SPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 9-(2-ACETOXYETHOXYMETHYL)GUANINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
INTERNATIONAL PHARMACOPEIA
Structure of 2-amino-9-[[2-(hydroxyethoxy) methoxy]methyl]-1,9-dihydro-6H-purin-6-one
IMPURITY -> PARENT
sum of impurities O and Q: not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) ( 0.15 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 2-((2-ACETAMIDO-6-OXO-1H-PURIN-7(6H)-YL)METHOXY)ETHYL ACETATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 9,9'-(2,5,7,10-TETRAOXAUNDECANE-1,11-DIYL)BIS(2-AMINO-1,9-DIHYDRO-6H-PURIN-6-ONE)
IMPURITY -> PARENT
sum of impurities K and R: not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.15 per cent)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of DIACETYLACYCLOVIR
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
INTERNATIONAL PHARMACOPEIA
Structure of O-((GUANIN-9-YL)METHYL) ACYCLOVIR
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of ACYCLOVIR
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Cmax PHARMACOKINETIC ROUTE OF ADMINSTRATION
PHARMACOKINETIC
DOSE
PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
ORAL BIOAVAILABILITY PHARMACOKINETIC
CSF/PLASMA RATIO PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966